Diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer

Abstract

Objective To study the diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer (NSCLC). Methods From January 2018 to March 2019, 22 patients with NSCLC in Daqing Longnan Hospital were selected as the study group, and 22 people who underwent health examination in our hospital during the same period were selected as the control group.The levels of serum microRNA21, major tumor markers and the relationship between pathological types and markers were observed and analyzed. Results The serum levels of miRNA-21 (2.15±0.9), CEA [(34.1±4.9)ng/mL], NSE [(27.1±2.2)ng/mL], and CYFRA21-1 [(12.1±1.2)ng/mL] in the study group were higher than those in the control group(t=6.524, 27.392, 23.339, 27.685, all P=0.000). The serum levels of miRNA-21 (1.88±1.14), CEA [(30.1±19.9)ng/mL], CYFRA21-1 [(12.8±5.2)ng/mL] in adenocarcinoma patients were lower than those in patients with squamous cell carcinoma, and the level of NSE [(26.1±3.2)ng/mL] was higher than that of patients with squamous cell carcinomas (t=1.158, 1.192, 0.423, 1.913, P=0.260, 0.247, 0.677, 0.070). The serum levels of miRNA-21 (2.58±0.96), CEA [(38.1±17.9)ng/mL], CYFRA21-1 [(16.8±6.2)ng/mL], NSE [(26.9±10.2)ng/mL] in NSCLC patients with Ⅲ~Ⅳ stage were higher than those in NSCLC patients with Ⅰ-Ⅱ stage, but only CYFRA21-1 had statistically significant difference(P<0.05), there were no statistically significant differences in the other three indicators (t=1.478, 0.574, 2.114, 1.015, P=0.155, 0.573, 0.047, 0.322). Conclusion The combined examination of serum microRNA-21 and tumor markers CEA, CYFRA21-1 and NSE in patients with NSCLC can effectively confirm the diagnosis, which is very important for the diagnosis, treatment and prognosis of patients.This diagnosis can be the first choice for patients with NSCLC. Key words: Carcinoma, non-small-cell lung; MicroRNA-21; Carcinoembryonic antigen; Cytokeratin 19-fragments; Neuron specific enolase; Early stage; Diagnostic value